Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Fexofenadine Hydrochloride	NCIT_C29050	[The hydrochloride salt form of fexofenadine, a carboxylated metabolic derivative of terfenadine and second generation, long-lasting selective histamine H1 receptor antagonist, with antihistaminic activity. Upon administration, fexofenadine competitively binds of peripheral H1-receptors in the gastrointestinal (GI) tract, blood vessels, and bronchial smooth muscle. This prevents binding of histamine to peripheral H1-receptors and prevents their activation. This prevents a histamine-mediated allergic reaction. Fexofenadine does not cross the blood-brain-barrier (BBB).]
Describe Usual Quality of Erections Without Assistance of Medicines or Devices During Last 4 Weeks	NCIT_C107642	[A question about how an individual would describe the usual quality of their erections without the assistance of medications or devices during the last four weeks.]
TSQM Version 1.4 - Time Takes Medication to Start Working	NCIT_C132620	[Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the amount of time it takes the medication to start working?]
Acetaminophen/Butalbital/Caffeine	NCIT_C29051	[A combination preparation of acetaminophen, butalbital, and caffeine. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis. Butalbital, a barbiturate with an intermediate duration of action, depresses the central nervous system and exerts sedative activity. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. This combination is used for the relief and treatment of migraine and tension headaches.]
Not Firm Enough for Sexual Activity	NCIT_C107643	[A response about an individual's erections not being firm enough for any sexual activity.]
TSQM Version 1.4 - Experience Any Side Effect at All	NCIT_C132621	[Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) As a result of taking this medication, do you experience any side effects at all?]
Sodium Phosphate/Sodium Biphosphate Laxative	NCIT_C29052	[An oral hyperosmotic saline laxative containing sodium biphosphate and sodium phosphate. Sodium phosphate/sodium biphosphate oral laxative promotes retention of water in the bowel, thereby increasing stool water content and volume, which results in increased gastrointestinal motility and stool transit time and evacuation of colonic contents.]
Firm Enough for Masturbation and Foreplay Only	NCIT_C107644	[A response about an individual's erections being firm enough for masturbation and foreplay only.]
TSQM Version 1.4 - How Bothersome Are Side Effects	NCIT_C132622	[Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How bothersome are the side effects of the medication you take to treat your condition?]
Fluocinolone	NCIT_C29053	[A synthetic glucocorticoid with anti-inflammatory and antipruritic activities. Fluocinolone binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinolone that interacts with and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinolone binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.]
Firm Enough for Intercourse	NCIT_C107645	[A response about an individual's erections being firm enough for intercourse.]
TSQM Version 1.4 - Interfere With Physical Health	NCIT_C132623	[Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what extent do the side effects interfere with your physical health and ability to function (i.e., strength, energy levels, etc.)?]
Flunisolide	NCIT_C29054	[A synthetic corticosteroid with antiinflammatory and antiallergic properties. Flunisolide is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation.]
TRAF7 Gene	NCIT_C107646	[This gene is involved in both MAPK signaling and protein ubiquitination.]
TSQM Version 1.4 - Interfere With Mental Function	NCIT_C132624	[Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what extent do the side effects interfere with your mental function (i.e., ability to think clearly, stay awake, etc.)?]
Fluocinolone Acetonide	NCIT_C29055	[The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.]
TRAF7 wt Allele	NCIT_C107647	[Human TRAF7 wild-type allele is located in the vicinity of 16p13.3 and is approximately 22 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRAF7 protein, plays a role in the positive regulation of both protein ubiquitination and MAPK signaling pathways.]
16p13.3	NCIT_C13646	[A chromosome band present on 16p]
TSQM Version 1.4 - Side Effect Affect Overall Satisfaction	NCIT_C132625	[Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what degree have medication side effects affected your overall satisfaction with the medication?]
Fluocinonide	NCIT_C29056	[A synthetic glucocorticoid and derivative of fluocinolone acetonide with anti-inflammatory and antipruritic activities. Fluocinonide binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinonide that interacts and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinonide binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.]